Study on the Accessibility of Pediatric-Specific Drugs in National Medical Insurance Negotiations
- VernacularTitle:国家医保谈判儿童专用药的可及性研究
- Author:
Na LI
1
;
Peng QI
;
Changsong JIANG
Author Information
1. 首都医科大学国家医疗保障研究院 北京 100037
- Publication Type:Journal Article
- Keywords:
insurance negotiation drug;
pediatric-specific drug;
drug accessibility
- From:
Chinese Health Economics
2025;44(10):69-74,83
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the accessibility of pediatric-specific drugs included in the National Medical Insurance Negotiated Drug List from 2020 to 2024.Methods:Using multi-source data,the accessibility of pediatric specific drugs was evaluated by analyzing the trend of changes in the number of drugs included in medical insurance,measuring accessibility and affordability.Results:The number of pediatric-specific drugs covered by national healthcare insurance negotiations increased annually,with a notable rise in Western medicines.Overall availability was relatively good,but regional distribution was uneven.Medications for common diseases showed better affordability,while those for rare diseases remained less affordable.Conclusion:The medical insurance negotiation policy has effectively improved the accessibility of pediatric medicines,but regional disparities and affordability challenges for rare disease treatments still require further improvement.It is recommended to optimize policies to reduce interregional disparities in drug availability and enhance the affordability of rare disease medications.
